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672Objective: To evaluate outcomes of systemic to pulmonary artery shunts (SPS) in patients weighing less than
3 kg with regard to shunt type, shunt size, and surgical approach.
Methods: Patients weighing less than 3 kg who underwent modified Blalock-Taussig or central shunts with pol-
ytetrafluoroethylene grafts at our institution from January 1, 2000, toMay 31, 2011, were reviewed. Patients who
had undergone other major concomitant procedures were excluded from the analysis. Primary outcomes
included mortality (discharge mortality and mortality before next planned palliative procedure or definitive
repair), cardiac arrest and/or extracorporeal membrane oxygenation (ECMO), and shunt reintervention.
Results: In this cohort of 80 patients, discharge survival was 96% (77/80). Postoperative cardiac arrest or
ECMO occurred in 6/80 (7.5%), and shunt reintervention was required in 14/80 (17%). On univariate analysis,
shunt reintervention was more common in patients with 3-mm shunts (11/30, 37%) compared with 3.5-mm
(2/36, 6%) or 4-mm shunts (1/14, 7%) (P<.003). There were no statistically significant associations between
shunt type, shunt size, or surgical approach and cardiac arrest/ECMO or mortality. Multiple logistic regression
demonstrated that a shunt size of 3 mm (P ¼ .019) and extracardiac anomaly (P ¼ .047) were associated with
shunt reintervention, whereas no variable was associated with cardiac arrest/ECMO or mortality.
Conclusions: In this high-risk group of neonates weighing less than 3 kg at the time of SPS, survival to discharge
and the next planned surgical procedurewas high. Outcomes were good with the 3.5- and 4-mm shunts; however,
shunt reintervention was common with 3-mm shunts. (J Thorac Cardiovasc Surg 2014;147:672-7)The neonatal systemic to pulmonary artery shunt (SPS) pro-
cedure continues to be associated with appreciable mortal-
ity. According to a recent harvest report of the STS
Congenital Heart Surgery Database (1/2013 report), mortal-
ity for a neonatal modified Blalock-Taussig shunt was
7.1%.1 Among the many factors accounting for this, small
patient size has consistently been reported as a risk factor
for worse outcomes.2-6 Given the limited size options of
commercially available shunts, it can be challenging in a
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The Journal of Thoracic and Cardiovascular Surgappropriate amount of pulmonary blood flow. In addition
to shunt size, other variables that could potentially modify
outcomes include shunt type (central shunt [CS], modified
Blalock-Taussig shunt [MBTS]) and surgical approach.
These surgically controllable factors and any potential rela-
tionships with outcomes in a high-risk group of neonates
weighing less than 3 kg at the time of SPS were evaluated
in this study.METHODS
Patients and Data Collection
Patient information was obtained retrospectively from the medical
records of all patients weighing less than 3 kg who underwent either a
CS or an MBTS with a polytetrafluoroethylene (Gore-Tex; W.L. Gore
and Associates, Inc, Newark, Del) graft at our institution between January
1, 2000, and May 31, 2011. Patients who had undergone other major
concomitant surgery (Norwood, Starnes procedure, unifocalization of
collaterals, and so forth) were excluded from the analysis; patch enlarge-
ment of the central pulmonary arteries was not an exclusion criterion.
Patients who had undergone autologous CS (eg, Melbourne shunt) due to
the absence of accurate information about shunt size were also excluded.
Patient information was deidentified, and study data were collected and
managed using REDCap electronic data capture tools hosted at the
Children’s Hospital of Wisconsin. The Institutional Review Board at the
Children’s Hospital of Wisconsin authorized the collection of data from
existing medical records under a waiver of the Health Insurance Portability
and Accountability Act (HIPAA) for this retrospective study.ery c February 2014
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
CS ¼ central shunt
ECMO ¼ extracorporeal membrane oxygenation
HIPAA ¼ Health Insurance Portability and
Accountability Act
MBTS ¼ modified Blalock-Taussig shunt
SPS ¼ systemic to pulmonary artery shunt
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DPatients were characterized according to diagnostic group, shunt type
(CS or MBTS), shunt size (3 mm, 3.5 mm, or 4 mm), and surgical approach
(thoracotomy or sternotomy). Diagnostic groups included pulmonary
atresia with ventricular septal defect, pulmonary atresia with intact ventric-
ular septum, anomalies with anticipated biventricular repair, and anomalies
with anticipated univentricular palliation. These groups were selected
according to the methods used by Petrucci and colleagues5 and the finding
that pulmonary atresia with intact ventricular septum was a risk factor for
mortality. Patient characteristics included diagnostic group, gestational
age, gender, weight at surgery, extracardiac/genetic anomalies, as well as
other factors with potential association with outcomes. Operative variables
included cardiopulmonary bypass time, aortic crossclamp time, approach
via thoracotomy or sternotomy, type of shunt, and size of shunt (Table 1).
Technique
All CS were created via a median sternotomy approach according to the
method reported by Gates and colleagues.7 Surgeon discretion determined
the use of thoracotomy versus sternotomy for MBTS, which was created
using standard techniques based on themethod of de Leval and colleagues,8
with the exception that the distal innominate artery was used for the
proximal anastomosis of the MBTS placed through a sternotomy. The
patient’s anatomy and clinical condition determined the use of cardiopul-
monary bypass (CPB). For off-pump cases, heparin was administered after
completion of the proximal anastomosis. Protamine was administered only
to patients who had been weaned from CPB. Postoperatively, heparin was
administered as a continuous infusion at 10-20 units/kg/h with conversion
to aspirin once enteral tolerance was achieved.
Outcomes
Primary outcomes measures included mortality, defined as death
occurring any time after the shunt procedure and before the next planned
palliation or definitive repair; postoperative cardiac arrest or extracorporeal
membrane oxygenation (ECMO); and shunt reintervention. Shunt
reintervention was defined as surgical or catheter-based intervention
to address inappropriate shunt flow (thrombus, anastomotic stenosis,
undersizing, oversizing).
Statistical Analysis
Descriptive characteristics of the sample were summarized by median
and interquartile range. A nonparametric Wilcoxon-Mann-Whitney test
or Kruskal-Wallis test was used to compare continuous variables. The c2
test or Fisher exact test was used to examine the associations in categorical
variables. Stepwise logistic regression was used to determine the important
covariates for various outcomes. Kaplan-Meier survival analysis was used
to assess death or intervention-free survival, with Wilcoxon log-rank
comparisons among the 3 shunt size groups. A competing risk analysis
was performed.9 Patients were grouped into 4 different categories: survived
without any reintervention; unplanned shunt reintervention; death before
any reintervention; and transition to definitive palliation or repair.The Journal of Thoracic and CaCumulative incidence functions among the shunt size groups for each event
were compared using the Gary test. All statistical tests were 2-tailed. All
analyses were done in SAS 9.2 (SAS Institute, Inc, Cary, NC).RESULTS
Preoperative and Operative Characteristics
The cohort included 80 patients with a median age and
weight at the time of SPS of 7 days (range, 1-79 days)
and 2.6 kg (range, 1.4-2.9 kg). Table 1 provides a compar-
ison of preoperative and operative characteristics according
to shunt type. Only 12 patients received a CS, and a higher
percentage of CS were 3 mm (9/12, 75%) compared with
21/68 (31%) of MBTS (P ¼ .021). As expected, all CS
were placed via a median sternotomy; whereas 25 of 68
(37%) MBTS were placed via thoracotomy. Also, use of
CPB was more common in the CS group (4/12, 33% for
CS vs 4/68, 6% for MBTS; P¼ .015). Other characteristics
were similar for both shunt type groups.
Table 2 provides a comparison of preoperative and oper-
ative characteristics for the 3 shunt size groups. More pa-
tients with 3-mm shunts demonstrated preoperative shock
or acidosis (P ¼ .010); prematurity (P<.0001); extracar-
diac anomalies (P ¼ .046); and a higher proportion of CS
(P ¼ .022). Table 3 compares preoperative and operative
characteristics according to surgical approach. A higher
percentage of patients undergoing sternotomy received a
3-mm shunt (28/55, 51%) compared with those undergoing
thoracotomy (2/25; 8%) (P< .001). The 2 groups were
otherwise similar.Outcomes
Hospital survival for the cohort was 96% (77/80). Of the
77 survivors, 91% (70/77) survived to definitive repair or
next planned palliation, and 4 patients died after repair or
next planned palliation. Causes of death included multiple
organ dysfunction syndrome (5 patients); unspecified (4 pa-
tients); sepsis (2 patients); meningitis (1 patient); cardiore-
spiratory failure (1 patient, unknown if overcirculation);
and shunt thrombosis (1 patient). Excluding mortality
occurring after the next planned procedure, on univariate
analysis there were no statistically significant associations
between mortality and diagnostic group, shunt type, shunt
size, or surgical approach (Table 4). Postoperative cardiac
arrest or use of ECMO occurred in 6/80 (7.5%) without as-
sociation with diagnostic group, shunt type, shunt size, or
surgical approach (Table 4).
Shunt reintervention occurred in 14/80 (17%); most were
done surgically. Five patients received a larger shunt; 5
received a same-size shunt (some in addition to existing
shunt); and 1 received a smaller shunt (coarctation of pul-
monary artery excluding flow from left MBTS to right
lung; second smaller shunt placed to right pulmonary artery
leaving previous shunt open). Shunt-related factors leading
to shunt reintervention included thrombus in 6 patients;rdiovascular Surgery c Volume 147, Number 2 673
TABLE 1. Patient characteristics versus shunt type
CS (N ¼ 12),
n (% of
column)
MBTS
(N ¼ 68),
n (% of
column)
P
value
PA-VSD 2 (17) 12 (18) .745
PA-IVS 3 (25) 16 (24)
BVR 4 (33) 30 (44)
UVP 3 (25) 10 (15)
Preoperative mechanical ventilation 5 (42) 25 (37) .746
Preoperative shock/acidosis 6 (50) 24 (35) .332
Surgical delay because of infection 1 (8) 5 (7) .999
Preoperative ECMO 0 0 .999
Weight at surgery
2 kg to 3 kg 11 (92) 63 (93) .999
<2 kg 1 (8) 5 (7)
Use of CPB 4 (33) 4 (6) .015
Genetic anomaly 2 (17) 15 (22) .999
Gestational age
37 wk 4 (33) 37 (54) .22
<37 wk 8 (67) 31 (46)
Extracardiac anomalies 3 (25) 19 (28) .999
Shunt size
3 mm 9 (75) 21 (31) .022
3.5 mm 2 (17) 34 (50)
4 mm 1 (8) 13 (19)
Surgical approach
Thoracotomy 0 25 (37) .014
Sternotomy 12 (100) 43 (63)
CS, Central shunt;MBTS, modified Blalock-Taussig shunt; PA-VSD, pulmonary atresia
with ventricular septal defect;PA-IVS, pulmonary atresiawith intact ventricular septum;
BVR, anticipated biventricular repair; UVP, anticipated univentricular palliation;
ECMO, extracorporeal membrane oxygenation; CPB, cardiopulmonary bypass.
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in 5 patients (inadequate flow, small pulmonary artery, and/
or coarctation of the pulmonary artery). Shunt reinterven-
tion was significantly associated with 3-mm shunts: 11/30
(37%) 3-mm shunts compared with 2/36 (6%) 3.5-mm
shunts and 1/14 (7%) 4-mm shunts (P<.003).
Logistic Regression
The relationship between surgically controllable factors
and outcomes was further assessed using logistic regression
analysis to account for differences in patient and operative
variables demonstrated in Tables 1-3. There were no
significant associations between diagnostic group, shunt
type, shunt size, or surgical approach with ECMO/cardiac
arrest or mortality. However, shunt size and extracardiac
anomaly were significantly associated with shunt
reintervention (P ¼ .019 for shunt size, P ¼ .047 for
extracardiac anomaly).
Competing Risk Analysis
In an analysis evaluating shunt size and competing risks
of survival without any reintervention; death before any674 The Journal of Thoracic and Cardiovascular Surgreintervention; transition to next planned palliation or defin-
itive repair; and transition to an unplanned shunt reinterven-
tion, the only statistically significant finding was a much
higher risk of transition to an unplanned shunt reinterven-
tion with 3-mm shunts (P ¼ .002); Figure 1 shows the
cumulative incidence curve.
DISCUSSION
Small patient size has been recognized as a significant
risk factor for worse outcomes after a neonatal SPS proce-
dure.2-6 Other than completing a technically excellent SPS
procedure, variables amenable to control by the surgeon
with potential to influence outcomes include shunt type
and size and operative approach. Therefore, the present
study was undertaken to assess whether or not these
variables were associated with important outcome
measures in this high-risk group of patients.
The main finding of our study is that 3-mm shunts were
associated with a substantially higher rate of shunt reinter-
vention. This is consistent with published results. Wells
and colleagues10 conducted a histopathologic analysis
of 155 explanted MBTS and reported smaller shunt size
(<4 mm) to be a risk factor for significant stenosis. Also,
O’Connor and colleagues11 reported smaller shunt size as
a significant risk factor for reintervention in MBTS. Other
investigators, however, have not found shunt size to be asso-
ciated with inferior outcomes for either MBTS or CS.3,6,12
Our data offer no reconciliation of these differences.
Although it is our impression that 3-mm shunts are associ-
ated with an increased risk of reintervention, the potential
importance of other factors, such as underlying anatomy
and physiology, size of the source arterial inflow, size of
the branch pulmonary arteries, ductal patency, degree of an-
ticoagulation, and technical factors related to different
methods of shunt placement, must be recognized.
Of the 14 reinterventions in our cohort, 11 occurred with
3-mm shunts; 5 of these involved upsizing the shunt. In
contrast, of the 3 reinterventions for 3.5- and 4-mm shunts,
only 1 involved placing a smaller shunt (this was a smaller
second shunt with the previous shunt left open). It is perhaps
surprising that to the extent congestive heart failure existed
in patients with larger shunts, it did not manifest in the out-
comes evaluated in our study. Also, shunt size remained
insignificant in an analysis (data not shown) in which mor-
tality was redefined to include death occurring after the next
planned procedure (in the event larger shunts unfavorably
predisposed patients for their next surgery). Although this
is not conclusive, it suggests that the lower durability of
3-mm shunts may offset any advantage related to more
restricted pulmonary blood flow. This should not neces-
sarily be inferred for CS or for patients weighing less than
2 kg, as these groups were underrepresented in our cohort,
and only 1 of 6 patients weighing less than 2 kg received
a shunt larger than 3 mm. Although no relationship betweenery c February 2014
TABLE 2. Patient characteristics versus shunt size
3 mm
(N ¼ 30),
n (% of
column)
3.5 mm
(N ¼ 36),
n (% of
column)
4 mm
(N ¼ 14),
n (% of
column)
P
value
PA-VSD 4 (13) 3 (8) 7 (50) .069
PA-IVS 7 (23) 11 (31) 1 (7)
BVR 13 (43) 16 (44) 5 (36)
UVP 6 (20) 6 (17) 1 (7)
Preoperative mechanical
ventilation
12 (40) 13 (36) 5 (36) .938
Preoperative shock/acidosis 16 (53) 13 (36) 1 (7) .01
Surgical delay because
of infection
4 (13) 2 (6) 0 .324
Preoperative ECMO 0 0 0 .999
Weight at surgery
2 kg to 3 kg 25 (83) 35 (97) 14 (100) .062
<2 kg 5 (17) 1 (3) 0
Use of CPB 6 (20) 2 (6) 0 .096
Genetic anomaly 6 (20) 7 (19) 4 (29) .769
Gestational age
37 wk 7 (23) 21 (58) 13 (93) <.0001
<37 wk 23 (77) 15 (42) 1 (7)
Extracardiac anomaly 12 (40) 5 (14) 5 (36) .046
Shunt type
CS 9 (30) 2 (6) 1 (7) .022
MBTS 21 (70) 34 (94) 13 (93)
Surgical approach
Thoracotomy 2 (7) 15 (42) 8 (57) <.001
Sternotomy 28 (93) 21 (58) 6 (43)
PA-VSD, Pulmonary atresia with ventricular septal defect; PA-IVS, pulmonary atresia
with intact ventricular septum; BVR, anticipated biventricular repair; UVP, antici-
pated univentricular palliation; ECMO, extracorporeal membrane oxygenation;
CPB, cardiopulmonary bypass; CS, central shunt; MBTS, modified Blalock-Taussig
shunt.
TABLE 3. Patient characteristics versus surgical approach
Thoracotomy
(N ¼ 25),
n (% of column)
Sternotomy
(N ¼ 55),
n (% of column)
P
value
Preoperative mechanical
ventilation
8 (32) 22 (40) .493
Preoperative shock/acidosis 6 (24) 24 (44) .093
Surgical delay because
of infection
0 6 (11) .169
Preoperative ECMO 0 0
Weight at surgery
2 kg to 3 kg 24 (96) 50 (91) .66
<2 kg 1 (4) 5 (9)
Genetic anomaly 7 (28) 10 (18) .32
Gestational age
37 wk 15 (60) 26 (47) .291
<37 wk 10 (40) 29 (53)
Extracardiac anomalies 5 (20) 17 (31) .311
Shunt size
3 mm 2 (8) 28 (51) <.001
3.5 mm 15 (60) 21 (38)
4 mm 8 (32) 6 (11)
ECMO, Extracorporeal membrane oxygenation.
TABLE 4. Outcomes versus shunt type, size, surgical approach, and
diagnostic group
Discharge or
late death,
n (% of row)
Cardiac arrest
or ECMO,
n (% of row)
Shunt
reintervention,
n (% of row)
Shunt type (n)
CS (12) 3 (25) 2 (17) 2 (17)
MBTS (68) 7 (10) 4 (6) 12 (18)
P value .168 .22 .999
Shunt size (n)
3 mm (30) 2 (7) 4 (13) 11 (37)
3.5 mm (36) 7 (19) 2 (6) 2 (6)
4 mm (14) 1 (7) 0 1 (7)
P value .263 .324 .003
Surgical approach (n)
Thoracotomy (25) 5 (20) 0 5 (20)
Sternotomy (55) 5 (9) 6 (11) 9 (16)
P value .272 .169 .755
Diagnostic groups (n)
PA-VSD (14) 3 (21) 1 (7) 3 (21)
PA-IVS (19) 2 (11) 0 1 (5)
BVR (34) 3 (9) 3 (9) 5 (15)
UVP (13) 2 (15) 2 (15) 5 (38)
P value .655 .354 .097
P values based on univariate analysis. See text for results of logistic regression.ECMO,
Extracorporeal membrane oxygenation; CS, central shunt; MBTS, modified Blalock-
Taussig shunt; PA-VSD, pulmonary atresia with ventricular septal defect; PA-IVS,
pulmonary atresia with intact ventricular septum; BVR, anticipated biventricular
repair; UVP, anticipated univentricular palliation.
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ineffective rescue therapy would further heighten concern
regarding 3-mm MBTS.
Our discharge survival of 96% compares favorably with
the range of 85%-94% reported by others for cohorts not
restricted to small patients.4-6,11-18 Recently, Petrucci and
colleagues5 reported on a multiinstitutional series from the
STS Congenital Heart Surgery Database of more than
1200 patients; 592 patients weighed between 1.5 and 3.0
kg at the time of SPS. Discharge survival was 84.4% in pa-
tients weighing 2-2.5 kg and 89% in all patients weighing
less than 3 kg. Another report by Erez and colleagues19 eval-
uated outcomes using saphenous vein homografts as shunts
in patients weighing less than 3 kg. In that series of 32 pa-
tients, hospital survival was approximately 94%, but overall
survival was approximately 80%. Neither of these 2 studies
offered a comparison between shunt size and type (CS or
MBTS) or surgical approach. Our cohort’s postdischarge
survival to next planned palliation or definitive repair was
somewhat higher than what has been reported by others in
cohorts not restricted to small patients.11,14-16,20 For ourThe Journal of Thoracic and Cacohort, it is not known if shunt-related deaths were truly un-
common or if proximate cause of death was simply not
discernable from the available documentation.rdiovascular Surgery c Volume 147, Number 2 675
FIGURE 1. Cumulative incidence of unplanned shunt reintervention
according to shunt size.
Congenital Heart Disease Myers et al
C
H
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nostic group, shunt type, and surgical approach were not
found in our study.2,4,5,12,17,21-25 Previous reports have
demonstrated inconsistent findings regarding these
issues. Factors that may in part account for our findings
include the weight restriction of the cohort and the
exclusion of patients undergoing other major
concomitant procedures. We presently prefer the median
sternotomy approach, as it offers much greater versatility
in determining proximal and distal shunt sites; permits
placement of the distal anastomosis more centrally,
which may favor more uniform development of the
branch pulmonary arteries; does not require collapse of
1 lung in a small, clinically unstable baby; and readily
permits use of CPB as needed to ensure patient stability.
We have not encountered major issues with sternal
reentry for subsequent planned surgeries.
Probably the main advantage of the CS is the avoidance
of branch pulmonary artery distortion and perhaps more
uniform distribution of blood flow. Also, particularly for a
small neonate, the shorter length of a CS permits a certain
degree of increased flow, which may be beneficial depend-
ing on the specific circumstance. However, based on other
features of shunts (such as technical ease of creation, provi-
sion of an appropriate amount of pulmonary blood flow, risk
of occlusion, ease of takedown, and so forth), it can be diffi-
cult to predict superiority of one shunt type over the other
for a small neonate.
An intuitively appealing explanation of our findings is
that neonates weighing less than 3 kg who require SPS pre-
sent with patient characteristics that are likely strong deter-
minants of outcome, regardless of the nonpatient, surgically
controllable factors. Nevertheless, our results suggest that a
3-mm diameter shunt may not be optimal for an isolated
MBTS in these patients.676 The Journal of Thoracic and Cardiovascular SurgLimitations
Our study is subject to the limitations and biases inherent
to a retrospective single-institutional study of a small
cohort. The group of patients receiving 3-mm shunts
seemed to have higher risk features and showed a statisti-
cally nonsignificant, but nonetheless more common use of
CPB for the shunt procedure. Despite using logistic regres-
sion to account for these and other patient variables, a con-
founding effect cannot be completely ruled out. One
controllable factor that we did not analyze was anticoagula-
tion, which could potentially be more important with
smaller shunts. Although patients received heparin and
aspirin, the degree of anticoagulation or antiplatelet effect
was not routinely assessed. Another limitation is the small
number of patients with CS, which limits the strength of
inference that may be made regarding these patients.
Because of the exclusion criteria in this study, our findings
do not necessarily apply to patients undergoing concomitant
major surgery. In addition, CS created from native pulmo-
nary arterial tissue were not assessed and no comment can
be made on the comparative advantages or disadvantages
of this approach.CONCLUSIONS
In this high-risk group of neonates weighing less than
3 kg at the time of SPS procedures, discharge survival
was high. Outcomes were good with 3.5- and 4-mm shunts;
however, shunt reintervention was common with 3-mm
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